[Federal Register Volume 61, Number 111 (Friday, June 7, 1996)]
[Notices]
[Pages 29103-29104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-14389]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has made final findings of scientific misconduct in the following
case:
Eric T. Fossel, Ph.D., Harvard Medical School: Based on ORI's
analysis of the relevant evidence and conclusions submitted by the
Harvard Medical
[[Page 29104]]
School Committee on Faculty Conduct, ORI found that Eric T. Fossel,
Ph.D., former Harvard Medical School Associate Professor of Radiology
at Beth Israel Hospital, committed scientific misconduct by reporting
falsified research results in a Public Health Service (PHS) grant
application.
Specifically, Dr. Fossel altered nuclear magnetic resonance (NMR)
data in the Multicenter Breast Trial (MCBT) such that the NMR test,
purporting to detect from a patient's blood sample a predisposition
toward malignancy or a relapse, appeared to be more accurate,
sensitive, and specific than was actually the case. Premised on these
falsely reported results, Dr. Fossel proposed in a PHS grant
application that the National Cancer Institute provide funds to
complete the MCBT.
Dr. Fossel has entered into a Voluntary Exclusion Agreement with
ORI in which he has voluntarily agreed, for the three (3) year period
beginning May 9, 1996, to exclude himself from:
(1) any contracting or subcontracting with any agency of the United
States Government and from eligibility for, or involvement in,
nonprocurement transactions (e.g., grants and cooperative agreements)
of the United States Government as defined in 45 CFR Part 76 (Debarment
Regulations), and
(2) serving in any advisory capacity to PHS, including but not
limited to service on any PHS advisory committee, board, and/or peer
review committee, or as a consultant.
No scientific publications were required to be corrected as part of
this Agreement.
FOR FURTHER INFORMATION CONTACT: Director, Division of Research
Investigations, Office of Research Integrity, 5515 Security Lane, Suite
700, Rockville, MD 20852.
Chris B. Pascal,
Acting Director, Office of Research Integrity.
[FR Doc. 96-14389 Filed 6-6-96; 8:45 am]
BILLING CODE 4160-17-P
